VIDEO: Hispanic, Black populations underrepresented in liver, biliary tract cancer trials
Click Here to Manage Email Alerts
Cecilia Monge, MD, MPH, FACP, from the NCI Center for Cancer Research at NIH, discussed her ASCO Gastrointestinal Cancers Symposium presentation on racial and ethnic disparities in liver and biliary tract cancer clinical trials.
In a video interview with Healio, Monge said there are high incidence rates of liver cancer among Hispanic and non-Hispanic Black populations, and the burden that liver cancer has on Hispanic individuals “is almost twice as that seen in non-Hispanic whites.”
After reviewing the literature, Monge and colleagues found that despite this, these populations are underrepresented in multinational phase 3 clinical trials studying liver and biliary tract cancer over the last 10 years.
Looking at the differences in incidence rate ratio by race and ethnicity showed “very steep underrepresentation,” and looking at clinical trial enrollment data each year over the last decade also showed underrepresentation, according to Monge.
Monge also said that this disparity in the Hispanic population “is relative to their representation in the U.S. population and also the relative burden that liver cancer and its incidence has in the Hispanic population.
“We think it’s important for phase 3 clinical trials that are seeking FDA approval to maybe require racial and ethnic diversity that is reflective of the U.S. population because these trials and the FDA approvals that may come with them then become guidelines that will be applied to the whole population,” she added.
Monge also talked about important ways to ensure proper representation of minority populations in future U.S. clinical trials.
Reference:
- Monge MC, et al. Abstract 497. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 19-21, 2023; San Francisco.
Collapse
Healio Interview
Click Here to Manage Email Alerts